B
13.97
0.03 (0.22%)
| Previous Close | 13.94 |
| Open | 13.90 |
| Volume | 1,459,732 |
| Avg. Volume (3M) | 1,122,933 |
| Market Cap | 615,024,128 |
| Price / Sales | 4.29 |
| Price / Book | 1.64 |
| 52 Weeks Range | |
| Earnings Date | 17 Feb 2026 |
| Profit Margin | -101.62% |
| Operating Margin (TTM) | -105.69% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | 36.40% |
| Total Debt/Equity (MRQ) | 2.22% |
| Current Ratio (MRQ) | 15.88 |
| Operating Cash Flow (TTM) | -56.10 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Beta Bionics, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | 1.0 |
| Insider Activity | -1.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.90 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 6.51% |
| % Held by Institutions | 98.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Lake Street, 186.33%) | Buy |
| Median | 23.50 (68.22%) | |
| Low | 14.00 (Baird, 0.22%) | Hold |
| Average | 25.17 (80.17%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 17.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 18 Feb 2026 | 14.00 (0.21%) | Hold | 13.61 |
| Stifel | 18 Feb 2026 | 22.00 (57.48%) | Buy | 13.61 |
| 04 Feb 2026 | 25.00 (78.95%) | Buy | 14.09 | |
| Truist Securities | 02 Feb 2026 | 25.00 (78.95%) | Buy | 13.70 |
| 18 Dec 2025 | 37.00 (164.85%) | Buy | 29.06 | |
| TD Cowen | 27 Jan 2026 | 17.00 (21.69%) | Hold | 14.93 |
| Lake Street | 09 Jan 2026 | 40.00 (186.33%) | Buy | 20.14 |
| B of A Securities | 05 Jan 2026 | 33.00 (136.22%) | Buy | 29.57 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEIDER STEPHEN | 12.63 | 12.52 | 130,115 | 1,643,510 |
| HOPMAN MARK | 12.63 | 11.95 | 107,918 | 1,363,537 |
| MENSINGER MIKE | 12.63 | 12.52 | 108,041 | 1,364,675 |
| RUSSELL STEVEN JON | 12.63 | 12.52 | 108,079 | 1,365,151 |
| SAINT SEAN | 12.63 | 12.52 | 339,885 | 4,293,120 |
| Aggregate Net Quantity | 794,038 | |||
| Aggregate Net Value ($) | 10,029,992 | |||
| Aggregate Avg. Buy ($) | 12.63 | |||
| Aggregate Avg. Sell ($) | 12.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOPMAN MARK | Officer | 04 Mar 2026 | Automatic sell (-) | 353 | 11.38 | 4,017 |
| MENSINGER MIKE | Officer | 02 Mar 2026 | Sell (-) | 1,064 | 12.52 | 13,321 |
| FEIDER STEPHEN | Officer | 02 Mar 2026 | Sell (-) | 1,428 | 12.52 | 17,879 |
| SAINT SEAN | Officer | 02 Mar 2026 | Sell (-) | 3,384 | 12.52 | 42,368 |
| RUSSELL STEVEN JON | Officer | 02 Mar 2026 | Sell (-) | 1,026 | 12.52 | 12,846 |
| HOPMAN MARK | Officer | 02 Mar 2026 | Sell (-) | 834 | 12.52 | 10,442 |
| MENSINGER MIKE | Officer | 27 Feb 2026 | Acquired (+) | 109,105 | 12.63 | 1,377,996 |
| FEIDER STEPHEN | Officer | 27 Feb 2026 | Acquired (+) | 131,543 | 12.63 | 1,661,388 |
| SAINT SEAN | Officer | 27 Feb 2026 | Acquired (+) | 343,269 | 12.63 | 4,335,487 |
| RUSSELL STEVEN JON | Officer | 27 Feb 2026 | Acquired (+) | 109,105 | 12.63 | 1,377,996 |
| HOPMAN MARK | Officer | 27 Feb 2026 | Acquired (+) | 109,105 | 12.63 | 1,377,996 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 15 Jan 2026 | Announcement | Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
| 08 Jan 2026 | Announcement | Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |